CV Therapeutics May Launch Ranexa In 2006, Hopes For Expanded Label
CV Therapeutics is planning for a potential 2006 launch for its pending chronic angina therapy Ranexa
You may also be interested in...
CV Therapeutics believes that it can resolve FDA's questions about potential testicular toxicity associated with the pending chronic angina therapy Ranexa (ranolazine) in the "short term.
CV Therapeutics' Ranexa could receive a restricted indication for use in refractory angina patients with a new study in that population, FDA's Cardiovascular & Renal Drugs Advisory Committee said Dec. 9
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011